Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2010

Open Access 01-11-2010 | Poster presentation

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays

Authors: G Fossati, A Nesbitt

Published in: Journal of Translational Medicine | Special Issue 1/2010

Login to get access

Excerpt

Differences in structure and in vitro properties of anti-TNF agents may account for different modes of action and clinical outcomes. The activities of certolizumab pegol (CZP), etanercept (ETA), infliximab (IFX) and adalimumab (ADA) have been compared using in vitro assays. [1] However, golimumab (GLM) has not previously been evaluated. …
Literature
1.
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T: Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007, 13: 1323-1332. 10.1002/ibd.20225.CrossRefPubMed
Metadata
Title
Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
Authors
G Fossati
A Nesbitt
Publication date
01-11-2010
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue Special Issue 1/2010
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-S1-P37

Other articles of this Special Issue 1/2010

Journal of Translational Medicine 1/2010 Go to the issue

Invited lecture presentation

HLA guided epitope discovery in Type 1 diabetes to generate novel therapeutics

Poster presentation

Genetic polymorphisms of inflammatory molecules in Tunisian inflammatory bowel diseases

Poster presentation

Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis

Poster presentation

BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single centre

Invited lecture presentation

Chemokines as inflammatory mediators of fibrosis in liver fibrosis

Poster presentation

Toll-like receptor ligands regulate the migratory pattern of leukocytes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits